We studied the feasibility and efficacy of a two-step approach to Auto-SCT for patients with AML in second remission.
Introduction
Although there has been considerable progress in the primary treatment of AML, many patients still relapse. For such patients, non-ablative chemotherapy offers little opportunity for prolonged disease-free survival (DFS), and treatment methods employing SCT are generally preferred. For younger patients with suitable HLAmatched donors, allo-SCT has been considered the treatment of choice with a 3-year DFS of 30-40%, although at a cost of overall treatment-related mortality (TRM) of 30-40%. However, many patients are not candidates for allogeneic transplantation due to older age, comorbid medical conditions or lack of a suitable donor. For these patients, autologous transplantation has emerged as an important treatment option. A number of studies have reported 3-year DFS of 25-40% with such an approach. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] There remain several concerns about the application of auto-SCT to patients with AML in second remission. Many patients intended to receive autologous transplants relapse prior to transplantation. In addition, there is great concern about the ability to collect adequate numbers of CD34 þ cells from these heavily pretreated patients. As primary therapy for AML increases in intensity with the more frequent use of high-dose cytarabine, this concern has heightened.
The CALGB study 9620 was initiated, with a target sample size of 48 patients, to evaluate on an intent-to-treat basis the feasibility and efficacy of a two-step approach to auto-SCT for patients with AML in second remission. We studied the ability of this approach to mobilize CD34 þ cells and to allow patients to proceed to transplantation without early relapse, as well as to study the overall efficacy of the approach in generating 2-year DFS, at which time most events would have occurred. We now report mature data from this study.
Materials and methods

Patient eligibility
Patients were eligible if they had an initial diagnosis of de novo AML and were in second CR (CR2). Patients with prior myelodysplasia, myeloproliferative diseases, therapyrelated AML or those who had received prior SCT were excluded. Any re-induction regimen was permitted, but patients could not have received any post-remission chemotherapy in CR2. They were required to be in CR2 for at least 30 days but o12 months, and to be 4age 15 and oage 70. CR2 was defined by having adequate peripheral blood counts with an ANC 41000/ml and plts 4100 000/ml, sustained for a minimum of 30 days.
Extramedullary leukemia must be absent and normal BM morphology with o5% blasts documented within 2 weeks of study entry. Cytogenetics were not required to confirm CR2, but if cytogenetics were performed and showed the persistence of a previously noted cytogenetic abnormality associated with AML, the patient was deemed not in CR even if morphologic remission were present. We required adequate laboratory function with bilirubin o1.5 mg per 100 ml, aspartate transaminase and alkaline phosphatase o3 times the upper limit of normal, and creatinine o2.0 mg per 100 ml. Each participant signed an IRBapproved, protocol-specific informed consent in accordance with federal and institutional guidelines after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side effects, risks and discomforts. Patient registration and data collection were managed by the CALGB Statistical Center. All data were carefully reviewed at the CALGB Statistical Center and by the study chairperson following standard CALGB policies to ensure the data quality.
Step 1-Consolidation chemotherapy All doses of chemotherapy in all phases of treatment were based on corrected weight calculated as ideal body weight plus 25% of the difference between actual and ideal body weight. For patients whose actual weight was 4150% of ideal, the actual weight was designated as 150% of ideal, and thus the corrected dose was calculated at 112.5% of ideal body weight.
Chemotherapy consisted of cytarabine 2000 mg/m 2 i.v. for over 2 h, every 12 h, for eight doses on days 1-4 plus etoposide 40 mg/kg by continuous i.v. infusion over 96 h on days 1-4. Cytarabine doses were adjusted according to renal function. The dose of cytarabine was reduced to 1000 mg/m 2 if the creatinine was 41.5 mg per 100 ml, and reduced to 200 mg/m 2 if the creatinine rose to 42.0 mg per 100 ml. G-CSF 10 mcg/kg s.c. daily was started on day 14 of the chemotherapy course. The PBSCs were collected according to institutional criteria when the white blood count was 410 000/ml. The target was to collect a CD34 þ cell dose of 45 Â 10 6 /kg with a minimum cell dose of 2.5 Â 10 6 /kg. Cells were cryopreserved and stored using institutional policies and guidelines.
Step 2-Auto-SCT Patients were eligible to proceed to transplantation if they had been out of the hospital for a minimum of 4 weeks and had no ongoing infection requiring antibiotic therapy. Remission status had to be confirmed with a BM exam showing normal morphology with o5% blasts within 2 weeks of admission for transplantation. We required an ANC 4500/ml and plts 45000/ml, and a CD34 þ cell dose X2.5 Â 10 6 /kg. Other eligibility requirements included lung diffusing capacity 450%, cardiac ejection fraction 440%, creatinine o2.0 mg per 100 ml, bilirubin o1.5 mg per 100 ml, aspartate transaminase and alkaline phosphatase o3 times the upper limit of normal.
The preparative regimen consisted of BU, 1 mg/kg orally every 6 h for 16 doses (total dose 16 mg/kg) on days À7 to À4, plus etoposide 60 mg/kg i.v. over 4 h on day À3.
Autologous PBSCs were thawed and infused on day 0. G-CSF 5 mcg/kg s.c. daily was started on day 0 and continued until ANC 41500/ml for 2 consecutive days, or 45000/ml for 1 day.
Supportive care
During step 1, antifungal prophylaxis was required and started on day 5 of therapy. Either amphotericin 0.3 mg/kg/ day i.v. or fluconazole 400 mg/day was allowed. Prophylaxis against gram-negative bacteria was recommended to start when ANC was o500/ml. Fluoromethalone 0.1% ophthalmic solution was administered four times per day on days 1-6.
During step 2, antifungal prophylaxis was required and started on day þ 1, continuing until ANC was 4500/ml. Either amphotericin 0.3 mg/kg/day i.v. or fluconazole 400 mg/day daily was permitted. Prophylactic antibacterial antibiotics against gram-negative bacteria were recommended starting when ANC was o500/ml. Acyclovir prophylaxis against herpesvirus infections was optional. Prophylaxis against Pneumocystis carinii infection was required and started at hospitalization, continuing for at least 3 months after transplantation or until the absolute CD4 þ lymphocyte count was 4200/ml. The recommended method was trimethoprim/sulfamethoxazole one doublestrength tablet twice daily for 2 days per week; drugs such as dapsone or pentamidine were permitted as substitutes. It was strongly recommended that patients shower twice daily from days À7 to À3 to decrease the incidence of skin toxicity associated with chemotherapy.
Statistical methods
Confidence intervals for binomial proportions were generated using the Clopper-Pearson method. 12 The discrepancy between two time-to-event distributions was assessed using the log-rank test. 13 The exact conditional sampling distribution of the log-rank statistic was approximated using B ¼ 10 000 permutation replicates. 14 The discrepancy between two binomial proportions was assessed using Fisher's test. 15 The P-value presented for the primary hypothesis, as specified in the protocol, is one-sided, whereas two-sided P-values were generated for all exploratory hypotheses. All confidence intervals presented are two-sided using a confidence level of 0.95. No adjustments for multiplicity were applied.
Statistical analysis was performed by responsible statisticians at the CALGB Statistical Center using the R 16 statistical environment to analyze the data and to generate the quantitative and graphical output presented in this paper.
Statistical evaluation
The primary clinical end point for this study was DFS, starting from entry on the study in CR2. Death from any cause was considered to be an event. The study was statistically designed with respect to the binary end point of being disease-free for at least 2 years following registration to the study. Henceforth, for notational brevity, we shall refer to this end point as 2-year DFS. It was hypothesized that the 2-year DFS probability exceeded 0.15. As per protocol, 48 patients were to be evaluated so as to have a level of significance of at most 0.05, a power of at least 0.81 for the one-sided local alternative that the 2-year DFS probability was 0.3. Feasibility and safety were secondary end points. Both of these end points were subject to interim analyses by a CALGB statistician and the study team. The database was frozen on 15 March 2007.
Results
Patient features
Fifty-one patients were enrolled between October 1996 and November 2000. There was broad representation from 18 different institutions, and the three largest accruing institutions contributed 44% of the patients. One patient was deemed ineligible because he was not in CR; thus, fifty patients were used in analysis.
The median patient age was 50 years (Table 1) . Thirtyeight patients were o60 years of age and had a median age of 47 years. Twelve patients were of age X60 years and had a median age of 64 years. Cytogenetics were available on 44 of the 50 patients. Thirteen patients had favorable cytogenetics, including seven with t(15;17), three with t(8;21) and three with inv (16) . Twenty-five patients had intermediate-risk cytogenetics; the karyotypes were normal in 22, had trisomy 8 in two patients and trisomy 6 in one. Three patients had poor risk cytogenetics, including one each with À5, À7 or a complex karyotype.
The median duration of first remission (CR1) had been 13.0 months. Ten patients had very short first remissions (p6 months), and 11 had CR1 durations between 7 and 11.8 months. Eighteen patients had a CR1 duration between 1 and 2 years, and nine had a CR1 duration 42 years.
Step 1-Consolidation chemotherapy Consolidation chemotherapy was generally well tolerated. Hematologic toxicity was as expected, with median time to ANC X500 of 20 days (Table 2) . Only one patient failed to resolve neutropenia by day 28 of therapy, and no patients had 43 total weeks of neutropenia. Transfusion requirements were modest for most patients. There was little nonhematologic toxicity. Most patients did not experience severe mucosal injury requiring parenteral nutrition or narcotic analgesia (Table 3) 
Stem cell collection
Stem cell collections started at a median of day 25 (Table 4) , and only four patients started later than day 30. Of 48 patients surviving this chemotherapy course, there are missing leukapheresis data on two patients, one of whom relapsed early and never proceeded to transplantation. Of 46 patients with complete data, 45 (98%) met the minimum goal of collecting a CD34 þ cell dose of X2.5 ( Â 10 6 /kg). The one other patient had a cell dose of 2.4 after one collection and did not receive additional collections for unclear reasons. Table 3 Non-hematologic toxicity
Step 1 (50 patients)
Step Ten patients had CD34 þ cell doses of o5. The median cell dose in this group was 3.6 and was achieved in three collections. Only five of these patients underwent extended collections with 5-7 aphereses. Twenty-two patients had CD34 þ cell doses between 5 and 9.9 (median, 5.6). This was achieved in a median of two collections; six of these patients underwent extended collections with 5-7 aphereses. Thirteen patients had CD34 þ cell doses of 410 (median, 14.6). These were collected in a median of two aphereses, but five of these patients had extended collections with 5-8 aphereses.
Step 2-Auto-SCT Forty-one patients (82% of the initial 50) proceeded to transplantation. Engraftment was generally rapid with modest need for transfusion support (Table 2) . Median time to ANC X1000/ml was day þ 10, and only two patients reached this landmark later than day þ 14. With a rapid neutrophil recovery, the median number of days spent with neutropenia was 9, and only one patient was neutropenic for 42 weeks. Time to neutrophil recovery was not affected by CD34 þ cell dose, with the median times to ANC 41000/ml between days þ 10 and þ 11 for patients with CD34 þ doses of o5, 5-10 and 410 ( Â 10 6 /kg). Plts generally engrafted quickly, but four patients required 430 days to reach plt counts of X20 000/ml. In addition, six patients took 460 days to reach plt counts of X50 000/ml, and 12 patients required 4100 days to reach plt counts of X 100 000/ml. Time to plt recovery was slower in patients who received lower CD34 þ cell doses. The median times to plts X50 000/ml was 14.5 (n ¼ 6), 18 (n ¼ 15) and 19 (n ¼ 5) days for those with CD34 þ cell doses of 410, 5-10 and o5 (Â 10 6 /kg), respectively. Similarly, the median times to plts X100 000/ml was 21 (n ¼ 6), 30.5 (n ¼ 10) and 29 (n ¼ 5) days for these same groups.
Non-hematologic toxicity was significant (Table 3) . Mucositis was generally moderate to severe. Although most patients did not require support with parenteral nutrition, 12 patients required 47 days of parenteral nutrition, and three patients required 414 days. Although the median number of days of narcotic analgesia was 5.5, 11 patients required 47 days and four patients required 414 days of narcotics. Hepatotoxicity was modest. Only three patients experienced bilirubin 43 mg per 100 ml, and none had bilirubin 410 mg per 100 ml or clinical venoocclusive disease.
There were four TRMs following transplantation, all among the 10 patients over the age of 60 years, who underwent transplantation. Two patients died from sepsis associated with delayed engraftment during their initial hospitalization. A third patient did well initially and was discharged on day þ 21, but was re-admitted on day þ 36 and died from Pseudomonas pneumonia. A fourth patient died 14 months after transplantation with pneumonia associated with pancytopenia. It could not be determined whether this pancytopenia was related to graft failure or myelodysplasia.
Treatment outcome
Fifty patients were entered on the study (Table 5) . Of these 50 patients, 17 were disease-free for at least 2 years following registration to the study. This corresponds to an empirical proportion of 0.34 (95% CI ¼ 0.21, 0.49). There is strong evidence that the probability of 2-year DFS exceeds 0.15 (one-sided P-value o0.0007). The productlimit estimates of DFS are illustrated in Figure 1 . The estimated median of the DFS distribution is 1.3 (0.68, 2.3) years. The estimated median of the overall survival distribution is 1.6 (1.4, 5.4) years. The Kaplan-Meier estimates are illustrated in Figure 2 . The median follow-up time was 8.2 (7.2-9.9) years, and the survival curves appear stable. The 5-year DFS is 0.28 (95% CI ¼ 0.16, 0.40).
During step 1, there were two TRMs. Of the 48 survivors, seven failed to proceed to transplant. Four patients experienced early relapse, one was ineligible to proceed because of a persistent low plt count, and two refused. One of these patients (with APL (acute promyelocytic leukemia)), who refused transplant, remains in continuous CR2 even after 5 years. Of 41 patients transplanted, there were four TRMs (10%) and 23 relapses (56%). The median time to relapse was 1.4 years (0.5-3.1), and only three relapses occurred later than 2 years.
There is strong evidence that the DFS distribution depends on FAB M3 status (P-value o0.0019). There is also strong evidence that the overall survival distribution depends on FAB M3 status (P-value o0.0045). The discrepancy in the DFS and overall survival profiles with There is no evidence that patients with long CR1 duration (at least 12 months) had better overall survival (P-value ¼ 0.19). However, age was a major prognostic factor. Patients over age 60 had a high TRM (5 of 12), and only two older patients had long-term DFS, including one patient with APL. Thus, only one of 11 non-APL older patients became a long-term survivor, corresponding to 5-year DFS of 0.1, whereas the projected 5-year DFS for younger non-APL patients was 0.18 (95% CI 0.04, 0.32).
Discussion
This CALGB study had broad participation across 18 centers and confirmed the feasibility and efficacy of this two-step approach to auto-SCT for patients with AML in CR2. Consolidation chemotherapy was generally well tolerated with only two (4%) deaths. The combination of this chemotherapy and G-CSF was highly effective in mobilizing the CD34 þ cells, despite the considerable prior myelosuppressive chemotherapy that these AML patients in CR2 had all received. 98% of patients achieved the minimum cell dose of X2.5 Â 10 /kg was achieved in three aphereses. Thus, although protracted apheresis was required in several patients, no patients failed to proceed to transplant because of an inadequate graft (the one patient who did not meet the minimum CD34 þ target had a CD34 þ cell dose of 2.4 Â 10 6 /kg and was permitted to proceed). Earlier reports have shown that the type of prior chemotherapy can affect engraftment following purged autologous BMT, and the use of PBSCs seems to largely overcome the adverse effect of prior treatment. 17 Overall, this consolidation and mobilization strategy allowed 82% of patients to proceed to transplantation. This same strategy has been highly successful in allowing a high percentage of patients with AML in CR1 to receive their intended autograft. 18 The CD34 þ cells resulted in rapid engraftment that likely contributed to the acceptable toxicity level of this aggressive transplant preparative regimen. The TRM was only 10% (4 of 41) overall, and none of the 29 patients under the age of 60 years experienced TRM. Overall, the program achieved its goal with 2-year DFS 430%, and the long-term DFS is 28%. With a median follow-up of 8.2 years (minimum, 7.1 years) and the latest relapse occurring at 2.5 years, these data are fully mature and unlikely to change.
This study confirms other reports on the good outcomes of patients with APL in CR2, achieving a DFS of 67%. 19, 20 This outcome was obtained despite the fact that our patients were not documented to be in molecular remission; this characteristic has been shown to predict superior longterm outcome after autografting. 21, 22 Auto-SCT may be the treatment of choice for such patients, even if a matched sibling donor were available. Given the TRM of at least 30% for allogeneic transplantation in CR2, it is unlikely to be a superior treatment. Recent European data also confirm that autologous transplantation is the treatment of choice in this setting. 21 However, given the dramatic improvement in the outcome of APL in first remission, the need for salvage therapy is a much less significant issue than it was earlier.
Despite prior single institution data on the safety of extending this autologous transplantation to AML patients over the age of 60 years, this CALGB study had an unacceptable TRM of 45% in this older age group. 3 It is possible that the use of i.v. BU and the adjustment of the BU dose based on pharmacokinetics could reduce the toxicity of the regimen.
In conclusion, CALGB has confirmed the efficacy of this treatment strategy in mobilizing adequate doses of CD34 þ cells from heavily pretreated patients with AML. A twostep procedure developed within a single center (UCSF) was successfully translated into a cooperative group study with equivalent results. Overall, this treatment program provides a potential curative option for patients with AML in second remission who are not candidates for allogeneic transplantation. 
